Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE
暂无分享,去创建一个
M. Jones-Lee | C. Donaldson | H. Mason | E. Lancsar | J. Wildman | M. Pennington | R. Baker | S. Chilton | H. Metcalf | Hugh R. T. Metcalf | Susan Chilton
[1] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[2] Dorte Gyrd-Hansen,et al. Estimating a WTP-based value of a QALY: the 'chained' approach. , 2013, Social science & medicine.
[3] I. Bateman,et al. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. , 2010, Health technology assessment.
[4] Richard D. Smith,et al. Contingent valuation: what needs to be done? , 2010, Health Economics, Policy and Law.
[5] C. Donaldson,et al. The impact of information on patient preferences in different delivery patterns: a contingent valuation study of prescription versus OTC drugs. , 2009, Health policy.
[6] M. Buxton,et al. Searching for cost effectiveness thresholds in the NHS. , 2009, Health policy.
[7] G. Loomes,et al. Trying to estimate a monetary value for the QALY. , 2009, Journal of health economics.
[8] N. Rice,et al. Does health care spending improve health outcomes? Evidence from English programme budgeting data. , 2008, Journal of health economics.
[9] Michael Jones-Lee,et al. Valuing lives equally: Defensible premise or unwarranted compromise? , 2008 .
[10] A. Tsuchiya,et al. The relative societal value of health gains to different beneficiaries: a summary , 2008 .
[11] C. Donaldson,et al. Managing to manage healthcare resources in the English NHS? What can health economics teach? What can health economics learn? , 2007, Health policy.
[12] Karl Claxton,et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.
[13] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[14] C E Phelps,et al. On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.
[15] Anthony J. Culyer,et al. The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.
[16] National Institute for Health and Clinical Excellence , 2010 .
[17] A. Culyer,et al. Pharmacoeconomics 2008; 26 (9): 733-744 , 2008 .
[18] Cam Donaldson,et al. The new myth: the social value of the QALY. , 2008, PharmacoEconomics.
[19] A. Holly,et al. The impact of information on patient preferences in different delivery patterns (prescription versus OTC drugs) , 2005 .
[20] A. Gafni,et al. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. , 2002, Health economics.